Gilde Healthcare sells its stake in Zetacom to facilitate a merger with Detron - Gilde Healthcare

Gilde Healthcare sells its stake in Zetacom to facilitate a merger with Detron

February 15, 2023
Utrecht & Zoetermeer (the Netherlands)

The Private Equity fund of Gilde Healthcare, the leading European specialist healthcare investor, has reached an agreement to sell its majority stake in Zetacom to Avedon Capital, a leading mid-market private equity firm in the Benelux and DACH-region. Avedon will merge the company with Detron, an independent IT service provider. The transaction is still subject to ACM approval.

Zetacom is a leading systems integrator for critical communication systems and networking & security solutions. It provides communication solutions mainly to healthcare institutions, but also some selected government bodies, corporates and SMEs. The company has offices in Zoetermeer, ‘s-Hertogenbosch and Apeldoorn from which it services the whole of the Netherlands.

Since Gilde Healthcare’s investment in 2015, the company more than doubled in size, while further building out its position in the Dutch healthcare market. Part of this growth was driven by three add-on acquisitions, whereby Gilde played an active role in facilitating, executing and financing the transactions. Through the intended merger with Detron, the combination will  become one of the largest independent managed services providers in the Netherlands.

Dick Dompeling, founder and CEO of Zetacom, stated: “Gilde Healthcare has played a transformative role in the development of our company. Since the entry of Gilde, we have focused on becoming the leader in critical healthcare communication. With our products and services we help hospitals and care homes to become more efficient and increase their quality of care. With rising costs and ongoing personnel shortages, this is crucial to our clients.

The merger with Detron is an exciting next step for Zetacom, whereby the combination offers many opportunities for both our clients and employees. Together, we are able to provide an even more complete offering to our healthcare clients.”

Hugo de Bruin, Partner at Gilde Healthcare, adds: “We are proud of what we achieved in the past years, doubling the company’s size by strategically expanding it in line with its clients’ needs. In doing so, Zetacom helped its healthcare clients to provide better care at lower cost, which it will continue to do going forward. We want to thank Dick and his team for this great journey, and wish them all the best in the combination with Detron.”

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.9 billion ($2.0 billion) across two fund strategies: Private Equity and Venture&Growth. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers to pharma, medtech and healthcare. Gilde Healthcare’s Venture&Growth fund invests in therapeutics, medtech and healthtech in Europe and North America. More information: www.gildehealthcare.com

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher...
November 20, 2023

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Gilde Healthcare Venture&Growth VI closes at its hard cap with €740 million from a balanced mix of international investors Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by...
November 15, 2023

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy...
October 17, 2023